JMP Securities Raises AnaptysBio, Inc. (ANAB) Price Target to $82.00
AnaptysBio, Inc. (NASDAQ:ANAB) had its target price increased by equities researchers at JMP Securities from $45.00 to $82.00 in a research report issued on Tuesday, The Fly reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. JMP Securities’ price objective suggests a potential upside of 134.29% from the stock’s current price.
Several other research firms have also weighed in on ANAB. Stifel Nicolaus restated a “buy” rating and set a $35.00 price target on shares of AnaptysBio in a research report on Tuesday, September 12th. Zacks Investment Research upgraded shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research report on Wednesday, September 13th. Royal Bank Of Canada began coverage on shares of AnaptysBio in a research report on Thursday, September 14th. They set an “outperform” rating and a $40.00 price target for the company. Robert W. Baird began coverage on shares of AnaptysBio in a research report on Monday, July 10th. They set an “outperform” rating and a $36.00 price target for the company. Finally, Credit Suisse Group increased their price target on shares of AnaptysBio from $34.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, August 25th. Seven research analysts have rated the stock with a buy rating, AnaptysBio currently has an average rating of “Buy” and a consensus target price of $42.14.
Shares of AnaptysBio (NASDAQ:ANAB) traded up 101.17% during mid-day trading on Tuesday, reaching $70.41. 5,788,406 shares of the company’s stock were exchanged. AnaptysBio has a 52-week low of $15.17 and a 52-week high of $70.48. The company’s market cap is $1.43 billion. The company’s 50-day moving average price is $34.23 and its 200 day moving average price is $34.23.
AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. The firm had revenue of $7.00 million during the quarter, compared to the consensus estimate of $3.45 million. On average, equities research analysts predict that AnaptysBio will post ($1.98) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “JMP Securities Raises AnaptysBio, Inc. (ANAB) Price Target to $82.00” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/10/jmp-securities-raises-anaptysbio-inc-anab-price-target-to-82-00.html.
In other news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total value of $901,924.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Holdings A/S Novo sold 70,706 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the completion of the transaction, the insider now owns 3,009,949 shares in the company, valued at approximately $70,161,911.19. The disclosure for this sale can be found here. Insiders have sold 1,133,940 shares of company stock worth $24,223,316 over the last quarter.
Several institutional investors have recently modified their holdings of the company. DAFNA Capital Management LLC grew its holdings in shares of AnaptysBio by 22.2% in the second quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 1,000 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of AnaptysBio by 23.4% in the second quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 1,807 shares during the last quarter. Bank of America Corp DE bought a new position in shares of AnaptysBio in the first quarter worth approximately $123,000. TIAA CREF Investment Management LLC grew its holdings in shares of AnaptysBio by 69.2% in the second quarter. TIAA CREF Investment Management LLC now owns 13,844 shares of the biotechnology company’s stock worth $331,000 after purchasing an additional 5,663 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of AnaptysBio by 46.8% in the second quarter. Bank of New York Mellon Corp now owns 19,744 shares of the biotechnology company’s stock worth $473,000 after purchasing an additional 6,297 shares during the last quarter. Hedge funds and other institutional investors own 71.35% of the company’s stock.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.